Founded in 2004, DIURNAL®, a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency.
Diurnal is dedicated to developing new treatments to aid lifelong treatment for rare and chronic endocrine conditions
Our expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body's natural hormone levels) to develop products for rare and chronic endocrine conditions
Diurnal is committed to transparency in its interactions. Diurnal commits to following the Association of British Pharmaceutical Industry (ABPI) Code of Practice which has clear requirements for transparency.
Diurnal is a rapidly growing global specialty pharmaceutical company with a highly integrated and very committed team. We're always looking for talented individuals who share our vision. Visit this section to view our current opportunities.
A limited number of awards is available each year, and all applications will be judged objectively by an independent panel.
This video is intended for patients who have been prescribed Alkindi and provides a step-by-step administration guide
Adverse events should be reported Reporting Forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse Events should also be reported to Diurnal on adverse-events@diurnal.co.uk